Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 8/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CCR4 | P51679 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049195 | 0.83 | KMT2A (0.66) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4548018 | 0.81 | GAA (1.00) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6799628 | 0.81 | RAB9A (0.55) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4560986 | 0.80 | GAA (0.77) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6798095 | 0.79 | ALOX5 (0.71) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14433270 | 0.77 | GAA (0.68) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11325137 | 0.77 | GAA (0.57) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5554730 | 0.76 | ALDH1A1 (0.52) | GAAKMT2ARAB9ASMN1; SMN2MAPT | |
| SCHEMBL13316453 | 0.74 | CCR4 (0.51) | GAAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15177819 | 0.74 | RAB9A (0.68) | GAAKMT2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736904-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB SCIENCE (FR) | 2016-03-16 | — | — | EP | disclosed |
| US-9168245-B2 | Selective protein kinase inhibitors | AB SCIENCE (FR) | 2015-10-27 | — | — | US | disclosed |
| US-20140179698-A1 | SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2014-06-26 | — | — | US | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179698-A1 | SELECTIVE PROTEIN KINASE INHIBITORS | KIT, MAP3K1, PRKCH | GAA 1334/4885KMT2A 735/4885RAB9A 876/4885 |
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | GAA 3522/4885KMT2A 968/4885RAB9A 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.